1 / 2

Multiple Sclerosis Therapeutics Market

The Global Multiple Sclerosis Therapeutics Market accounted for US$ 24.03 billion in 2020 and is estimated to be US$ 30.62 billion by 2030 and is anticipated to register a CAGR of 2.50%. Herbal medicine (also herbalism) is that the study of pharmacognosy and therefore the use of medicinal plants, which are a basis of traditional medicine. There is limited scientific evidence for the security and efficacy of plants utilized in 21st century herbalism, which generally doesn't provide standards for purity or dosage. The scope of herbal medicine commonly includes fungal and bee products, also as mi

aishwarya25
Download Presentation

Multiple Sclerosis Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Global Multiple Sclerosis Therapeutics Market accounted for US$ 24.03 billion in 2020 and is estimated to be US$ 30.62 billion by 2030 and is anticipated to register a CAGR of 2.50%. Herbal medicine (also herbalism) is that the study of pharmacognosy and therefore the use of medicinal plants, which are a basis of traditional medicine. There is limited scientific evidence for the security and efficacy of plants utilized in 21st century herbalism, which generally doesn't provide standards for purity or dosage. The scope of herbal medicine commonly includes fungal and bee products, also as minerals, shells and certain animal parts. Herbal medicine is additionally called phytomedicine or phytotherapy. The report “Global Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030” Key Highlights: In 2021, U.S. FDA approves J&J's multiple sclerosis treatment; launch in April. (Reuters) - Johnson & Johnson will launch its newly approved drug for adults with relapsing multiple sclerosis (MS) in the United States in early April 2021 at a similar price point to rival treatments. Analyst View: Currently, there is no cure for MS however; number of treatment can help to control the condition. Treatment modalities are depends on specific symptoms and difficulties of patient, which includes treating relapses with short courses of steroid medication, disease modifying therapies, and specific treatments for individual MS symptoms. Increasing prevalence of multiple sclerosis among the global population, along with extensive research and development (R&D) activities undertaken by key players and government research organizations will accelerate the market growth. Browse 60 maret data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030” To know the upcoming trends and insights prevalent in this market, click the link below: https://www.prophecymarketinsights.com/market_insight/Global-Multiple-Sclerosis- Therapeutics-Market-54

  2. Key Market Insights from the report: The Global Multiple Sclerosis Therapeutics Market accounted for US$ 24.03 billion in 2020 and is estimated to be US$ 30.62 billion by 2030 and is anticipated to register a CAGR of 2.50%. The global multiple sclerosis therapeutics market has been segmented on the basis of drug class, route of administration, distribution channel, and region. By Drug Class, the Global Multiple Sclerosis Therapeutics Market is segmented into Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others. By Route of Administration, the Global Multiple Sclerosis Therapeutics Market is segmented into Oral and Injectable. By Distribution Channel, the Global Multiple Sclerosis Therapeutics Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the Global Multiple Sclerosis Therapeutics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the multiple sclerosis therapeutics market. Factors responsible for growth of the market includes substantial rise in the awareness among the people regarding various risk factors to cause multiple sclerosis. Competitive Landscape: Key players operating in the global multiple sclerosis therapeutics market includes Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck KGaA, Biogen Inc., Sanofi S.A., F. Hoffmann-La Roche AG, AbbVie, Inc., and Pfizer, Inc. other related reports: https://sites.google.com/d/1a9Bdd3fIQBtQO8wlgLyICOwWShdLU15m/p/16YDoe1YnCt9QZkYtb RhoAd1eUOqAYAyn/edit https://aishwarya-16.blogspot.com/2023/02/coronary-stent-market-is-estimated-to.html https://aishwarya-16.blogspot.com/2023/02/coronary-stent-market-is-estimated-to.html

More Related